Rapid and sustained response to luspatercept and eltrombopag combined treatment in one case of clonal cytopenias of undetermined significance with prior failure to cyclosporin and androgen therapy: a case report

• Published in: Therapeutic advances in hematology Vol. 15; p. 20406207241260353
• Main Authors: Xu, Jing, Yan, Yixin, Zong, Siwen, Ye, Wencan, Zheng, Jifu, Min, Chao, Wang, Qingming, Li, Zhenjiang
• Format: Journal Article
• Language: English
• Published: England SAGE Publications 01.01.2024; SAGE Publishing
• Subjects: Case Report; case report; clonal cytopenias of undetermined significance; luspatercept; rapid and sustained remission; eltrombopag
• ISSN: 2040-6207; 2040-6215
• DOI: 10.1177/20406207241260353

Clonal cytopenia of undetermined significance (CCUS) has the characteristics of high-risk transformation into myelodysplastic syndromes. At present, there are few effective treatments for CCUS, and there is no consensus or evidence-based recommendation. We present a case demonstrating a rapid, significant and sustained response to combined treatment with luspatercept and eltrombopag, following the failure of cyclosporin and androgen therapy. Even after discontinuing luspatercept for 10 months, trilineage haematopoiesis remained normal with the use of cyclosporin and other haematopoietic stimulants. This case suggests that the inhibition of transforming growth factor-β could potentially have an immunomodulatory effect, thereby promoting the recovery of haematopoietic function. Luspatercept, along with Acalabrutinib or Cyclosporine, may synergistically stimulate haematopoiesis.